<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882293</url>
  </required_header>
  <id_info>
    <org_study_id>SIL-30301-III-20(1)</org_study_id>
    <nct_id>NCT04882293</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.</brief_title>
  <official_title>Confirmatory Study of the Efficacy and Safety of the Fixed-dose Combination Atorvastatin / Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients With Type 2 Diabetes (T2D) and Dyslipidaemia (DLP).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase IIIb, randomized, longitudinal, prospective, multicenter study to evaluate the efficacy&#xD;
      and safety of the fixed-dose combination atorvastatin / fenofibrate versus atorvastatin on&#xD;
      the lipid profile of patients with type 2 diabetes and dyslipidemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the efficacy and safety of the fixed-dose combination atorvastatin / fenofibrate&#xD;
      versus atorvastatin on the lipid profile of patients with type 2 diabetes and dyslipidemia.&#xD;
      Assessing the magnitude of change in lipid profile numbers. And describing the effect on&#xD;
      anthropometric, biochemical and clinical indicators, as well as events and adverse reactions&#xD;
      that may occur. In patients diagnosed with type 2 diabetes and dyslipidemia (triglycerides&gt;&#xD;
      150 mg / dl, LDL (Low density lipoprotein) cholesterol&gt; 100 mg / dl) and who require&#xD;
      pharmacological treatment for lipid control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Magnitude of change in lipid profile figures.</measure>
    <time_frame>Baseline, 2 and 4 months.</time_frame>
    <description>To assess the magnitude of change in lipid profile figures (Lp [a], LDL, and triglycerides) at 2 and 4 months with respect to their baseline measurement and between treatment groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects achieving triglyceride levels &lt;150 mg /dL.</measure>
    <time_frame>4 months</time_frame>
    <description>Describe the proportion of subjects who achieved triglyceride levels &lt;150 mg / dL at the end of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe the proportion of subjects who reduced levels of LDL cholesterol</measure>
    <time_frame>Baseline and 4 months.</time_frame>
    <description>Describe the proportion of subjects who reduced levels of LDL cholesterol, under 30% compare to the baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact on anthropometric indicators (Weight)</measure>
    <time_frame>Baseline and 4 Months</time_frame>
    <description>Describe changes in weight (kg) measurements from baseline to the end of the study (4 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on anthropometric indicators body mass index (BMI)</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>Describe changes in BMI (kg/m2) from baseline to the end of the study (4 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on anthropometric indicators (Waist circumference)</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>Describe changes in waist circumference (cm) from baseline to the end of the study (4 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on liver function with aspartate aminotransferas (AST)</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>Describe the changes in AST (mg/dL) concentration, between baseline and the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on liver function with Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>Describe the changes in ALT (mg/dL) concentration, between baseline and the end of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on Glycosylated hemoglobin (HbA1c)</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>Describe the changes in HbA1c percentage from baseline to the end of the study (4 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on glucose levels</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>Describe the changes in glucose levels (mg/dL) from baseline to the end of the study (4 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on Blood pressure</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>Describe the changes in blood pressure (mm Hg) from baseline to the end of the study (4 months). impact on clinical indicators (Blood pressure, Heart rate, Respiratory rate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on heart rate</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>Describe the changes in heart rate (beats per minute) from baseline to the end of the study (4 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on respiratory rate</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>Describe the changes in respiratory rate (Pulses per minute) from baseline to the end of the study (4 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events and adverse reactions presented.</measure>
    <time_frame>4 months</time_frame>
    <description>Proportion of events and adverse reactions presented during 4 months of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Dyslipidemia Associated With Type II Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group A: Atorvastatin / Fenofibrate in fixed dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: Atorvastatin / Fenofibrate in fixed dose Pharmaceutical Form: Tablets Dosage: 20 mg /160 mg Adminstration way: Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Atorvastatin (Lipitor ®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: Atorvastatin (Lipitor ®) Pharmaceutical Form: Tablets Dosage: 20 mg Adminstration wat: Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose</intervention_name>
    <description>1 tablet once a day, 20 mg /160 mg, Orally</description>
    <arm_group_label>Group A: Atorvastatin / Fenofibrate in fixed dose</arm_group_label>
    <other_name>ATV / FENO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin (Lipitor ®)</intervention_name>
    <description>1 tablet once a day, 20 mg, Orally</description>
    <arm_group_label>Group B: Atorvastatin (Lipitor ®)</arm_group_label>
    <other_name>ATV (Lipitor ®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  That the subject agrees to participate in the study and gives their informed consent&#xD;
             in writing.&#xD;
&#xD;
          -  Both genres.&#xD;
&#xD;
          -  Age 18 to 75 years old.&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes mellitus with adequate glycemic control defined by HbA1c&#xD;
             ≤ 7.5% at the time of selection.&#xD;
&#xD;
          -  Diagnosis of dyslipidemia prior to the start of the study (LDL cholesterol&gt; 100 mg /&#xD;
             dl and triglycerides&gt; 150 mg / dl).&#xD;
&#xD;
          -  Willing to avoid sexual contact or to use a barrier method of contraception while&#xD;
             conducting the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The drug is contraindicated for medical reasons.&#xD;
&#xD;
          -  Consumption of oral contraceptives, cyclosporine or strong cytochrome p450 (CYP) 3A4&#xD;
             inhibitors, protease inhibitors, erythromycin and azoles.&#xD;
&#xD;
          -  Patients with Type 1 Diabetes Mellitus.&#xD;
&#xD;
          -  Acute or Severe renal dysfunction (glomerular filtration &lt;30 ml / min / 1.72 m2).&#xD;
&#xD;
          -  History of chronic liver disease or ALT and / or AST ≥ 2 times the upper limit of&#xD;
             normal, or GGT ≥3 times the upper limit of normal.&#xD;
&#xD;
          -  Chronic or acute pancreatitis except for acute pancreatitis due to severe&#xD;
             hypertriglyceridemia (defined by the presence of triglycerides&gt; 1000 mg / dl and / or&#xD;
             milky plasma, in the absence of other etiological factors of pancreatitis).&#xD;
&#xD;
          -  Patients with active gallbladder disease (defined as acute or chronic gallbladder&#xD;
             disorders associated with clinical signs or symptoms).&#xD;
&#xD;
          -  Patient with a history or presence of myopathies.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Known contraindication or hypersensitivity to the use of any of the components of the&#xD;
             investigational drug.&#xD;
&#xD;
          -  The patient is participating in another clinical study involving an investigational&#xD;
             treatment or participated in one in the previous 4 weeks.&#xD;
&#xD;
          -  At the medical discretion, a disease that affects the prognosis and prevents&#xD;
             outpatient management, for example, but not restricted to: end-stage cancer, kidney,&#xD;
             heart, respiratory or liver or mental failure or with scheduled surgical or hospital&#xD;
             procedures.&#xD;
&#xD;
          -  Be a patient with a working relationship with the principal investigator or the&#xD;
             research center or prisoner.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto J Zamora Muciño-Arroyo, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V. (BIOMED-AGS)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Rodríguez Saldaña, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Resultados médicos, desarrollo e investigación SC (REMEDI)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco G Padilla Padilla, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Independent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan A Peraza Zaldivar, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigación Biomédica para el Desarrollo de Fármacos S.A. de C.V. (BIOMED-GDL)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis M Román Pintos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Hispano S.A de C.V</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorge A González, PhD</last_name>
    <phone>5254883785</phone>
    <phone_ext>3761</phone_ext>
    <email>jogonzalez@silanes.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yulia G Romero-Antonio, B.S.</last_name>
    <phone>5554883700</phone>
    <phone_ext>3777</phone_ext>
    <email>yromero@silanes.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratorio Silanes, S.A. de C.V.</name>
      <address>
        <city>Mexico City</city>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Jorge A Gonzalez, PhD</last_name>
      <phone>+5254883785</phone>
      <phone_ext>3761</phone_ext>
      <email>jogonzalez@silanes.com.mx</email>
    </contact>
    <contact_backup>
      <last_name>Yulia Romero-Antonio, B.S.</last_name>
      <phone>5554883700</phone>
      <phone_ext>3777</phone_ext>
      <email>yromero@silanes.com.mx</email>
    </contact_backup>
    <investigator>
      <last_name>Alberto J Zamora Muciño-Arroyo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel Rodríguez Saldaña, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco G Padilla Padilla, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan A Peraza Zaldicar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis M Román Pintos, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://www.dof.gob.mx/nota_detalle.php?codigo=5259329&amp;fecha=13/07/2012</url>
    <description>NOM. 037-SSA2-2012 para la prevención, tratamiento y control de las dislipidemias. México: Diario Oficial de la Federación. 2012;13.</description>
  </link>
  <reference>
    <citation>Escobedo-de la Peña J, de Jesús-Pérez R, Schargrodsky H, Champagne B. [Prevalence of dyslipidemias in Mexico city and Its relation to other cardiovascular risk factors. Results from the CARMELA study]. Gac Med Mex. 2014 Mar-Apr;150(2):128-36. Spanish.</citation>
    <PMID>24603993</PMID>
  </reference>
  <reference>
    <citation>Harivenkatesh N, David DC, Haribalaji N, Sudhakar MK. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial. J Cardiovasc Pharmacol Ther. 2014 May;19(3):296-303. doi: 10.1177/1074248413518968. Epub 2014 Feb 10.</citation>
    <PMID>24516261</PMID>
  </reference>
  <reference>
    <citation>Lella M, Indira K. A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia. J Adv Pharm Technol Res. 2013 Jul;4(3):166-70. doi: 10.4103/2231-4040.116778.</citation>
    <PMID>24083205</PMID>
  </reference>
  <reference>
    <citation>Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002 Jul;25(7):1198-202.</citation>
    <PMID>12087019</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <keyword>Lipid profile</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

